Cargando…
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
BACKGROUND: Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two ca...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058104/ https://www.ncbi.nlm.nih.gov/pubmed/21366910 http://dx.doi.org/10.1186/1471-2407-11-90 |
_version_ | 1782200345608323072 |
---|---|
author | Guo, Renhua Chen, Xiaofen Wang, Tongshan Zhang, Zhiyuan Sun, Jin Shu, Yongqian |
author_facet | Guo, Renhua Chen, Xiaofen Wang, Tongshan Zhang, Zhiyuan Sun, Jin Shu, Yongqian |
author_sort | Guo, Renhua |
collection | PubMed |
description | BACKGROUND: Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC who developed resistance to TKI. CASE PRESENTATION: Two patients with advanced or metastatic NSCLC were treated with palliative chemotherapy followed by erlotinib/gefitinib. When TKI therapy failed, two cycles of chemotherapy were provided, which were followed by re-challenge with erlotinib or gefitinib. CONCLUSION: NSCLC patients with acquired TKI resistance should be managed aggressively whenever possible. Subsequent chemotherapy and target treatment is one of the reasonable choices for those with an initial dramatic clinical response with erlotinib/gefitinib treatment. Further studies are warranted to substantiate the association of erlotinib /gefitinib treatment with the efficacy of NSCLC patients with acquired TKI failure. |
format | Text |
id | pubmed-3058104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30581042011-03-16 Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer Guo, Renhua Chen, Xiaofen Wang, Tongshan Zhang, Zhiyuan Sun, Jin Shu, Yongqian BMC Cancer Case Report BACKGROUND: Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC who developed resistance to TKI. CASE PRESENTATION: Two patients with advanced or metastatic NSCLC were treated with palliative chemotherapy followed by erlotinib/gefitinib. When TKI therapy failed, two cycles of chemotherapy were provided, which were followed by re-challenge with erlotinib or gefitinib. CONCLUSION: NSCLC patients with acquired TKI resistance should be managed aggressively whenever possible. Subsequent chemotherapy and target treatment is one of the reasonable choices for those with an initial dramatic clinical response with erlotinib/gefitinib treatment. Further studies are warranted to substantiate the association of erlotinib /gefitinib treatment with the efficacy of NSCLC patients with acquired TKI failure. BioMed Central 2011-03-02 /pmc/articles/PMC3058104/ /pubmed/21366910 http://dx.doi.org/10.1186/1471-2407-11-90 Text en Copyright ©2011 Guo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Guo, Renhua Chen, Xiaofen Wang, Tongshan Zhang, Zhiyuan Sun, Jin Shu, Yongqian Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
title | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
title_full | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
title_fullStr | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
title_full_unstemmed | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
title_short | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
title_sort | subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058104/ https://www.ncbi.nlm.nih.gov/pubmed/21366910 http://dx.doi.org/10.1186/1471-2407-11-90 |
work_keys_str_mv | AT guorenhua subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT chenxiaofen subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT wangtongshan subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT zhangzhiyuan subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT sunjin subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT shuyongqian subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer |